Citations

Mayo Clinic

Clear

2509 citation(s) found for "Yang, Mo".

Spectral and spatial shifts of post-ictal slow waves in temporal lobe seizures
Yang, Lin , Nelson, Cindy, Brinkmann, Benjamin H. , He, Bin , Worrell, Gregory A. , Brinkmann, Benjamin H , He, Bin

Brain | August 24, 2012 | Volume: 135 | Issue: 10 | Pages: 3134-3143

10.1093/brain/aws221 | PMID 22923634 Get It

Faculty Opinions recommendation of MicroRNA expression, survival, and response to interferon in liver cancer.
Yang, Ju Dong , Roberts, Lewis R. , Yang, Ju Dong

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | August 21, 2012 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.1382977.855077 Get It

Faculty Opinions recommendation of Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression.
Yang, Ju Dong , Roberts, Lewis R. , Yang, Ju Dong

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | August 21, 2012 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.1954966.2426055 Get It

Faculty Opinions recommendation of Nomograms for risk of hepatocellular carcinoma in patients with chronic hepatitis B virus infection.
Yang, Ju Dong , Roberts, Lewis R. , Yang, Ju Dong

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | August 21, 2012 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.3593957.3303055 Get It

Faculty Opinions recommendation of Use of surveillance for hepatocellular carcinoma among patients with cirrhosis in the United States.
Yang, Ju Dong , Roberts, Lewis R. , Yang, Ju Dong

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | August 21, 2012 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.4333956.4155054 Get It

Faculty Opinions recommendation of Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma.
Yang, Ju Dong , Roberts, Lewis R. , Yang, Ju Dong

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | August 20, 2012 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.6687956.6843054 Get It

Faculty Opinions recommendation of A unique metastasis gene signature enables prediction of tumor relapse in early-stage hepatocellular carcinoma patients.
Yang, Ju Dong , Roberts, Lewis R. , Yang, Ju Dong

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | August 20, 2012 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.7510958.7806056 Get It

Faculty Opinions recommendation of Utilization of surveillance for hepatocellular carcinoma among hepatitis C virus-infected veterans in the United States.
Yang, Ju Dong , Roberts, Lewis R. , Yang, Ju Dong

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | August 20, 2012 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.9061956.9636054 Get It

Faculty Opinions recommendation of Metabolic syndrome increases the risk of primary liver cancer in the United States: a study in the SEER-Medicare database.
Yang, Ju Dong , Roberts, Lewis R. , Yang, Ju Dong

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | August 20, 2012 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.13122956.14447054 Get It

Molecular characterization of mucinous ovarian tumours supports a stratified treatment approach with HER2 targeting in 19% of carcinomas
Anglesio, Michael S. , Kommoss, Stefan , Tolcher, Mary Catherine , Clarke, Blaise , Galletta, Laura, Porter, Henry, Damaraju, Sambasivarao , Fereday, Sián , Winterhoff, Boris , Yang, Winnie , Steed, Helen , Allo, Ghassan , Ferguson, Sarah E. , Teoman, Attila, García, Joaquín J. , Schoolmeester, John K., Tinker, Anna V. , Bowtell, David D.L. , Huntsman, David G. , Gilks, C. Blake, Kalloger, Steve E. , Senz, Janine , Shaw, Patricia H. , Bakkum‐Gamez, Jamie N. , McAlpine, Jessica N. , Anglesio, Michael S , Bowtell, David D , Fereday, Sian , Steed, Helen

The Journal of Pathology | August 16, 2012 | Volume: 229 | Issue: 1 | Pages: 111-120

10.1002/path.4088 | PMID 22899400 Get It

AbstractMucinous ovarian carcinomas (MCs) typically do not respond to current conventional therapy. We have previously demonstrated amplification of HER2 in 6 of 33 (18.2%) mucinous ovarian carcinomas (MCs) and presented anecdotal evidence of response with HER2‐targeted treatment in a small series of women with recurrent HER2‐amplified (HER2+) MC. Here, we explore HER2 amplification and KRAS mutation status in an independent cohort of 189 MCs and 199 mucinous borderline ovarian tumours (MBOTs) and their association to clinicopathological features. HER2 status was assessed by immunohistochemistry (IHC), FISH, and CISH, and interpreted per ASCO/CAP guidelines, with intratumoural heterogeneity assessment on full sections, where available. KRAS mutation testing was performed with Sanger sequencing. Stage and grade were associated with recurrence on both univariate and multivariate analysis (p < 0.001). Assessment of HER2 status revealed overexpression/amplification of HER2 in 29/154 (18.8%) MCs and 11/176 (6.2%) MBOTs. There was excellent agreement between IHC, FISH, and CISH assessment of HER2 status (perfect concordance of HER2 0 or 1+ IHC with non‐amplified status, and 3+ IHC with amplified status). KRAS mutations were seen in 31/71 (43.6%) MCs and 26/33 (78.8%) MBOTs, and were near mutually exclusive of HER2 amplification. In the 189 MC cases, a total of 54 recurrences and 59 deaths (53 of progressive disease) were observed. Within MCs, either HER2 amplification/overexpression or KRAS mutation was associated with decreased likelihood of disease recurrence (p = 0.019) or death (p = 0.0041) when compared to cases with neither feature. Intratumoural heterogeneity was noted in 26% of HER2‐overexpressing cases. These data support the stratification of MCs for the testing of new treatments, with HER2‐targeted therapy as a viable option for HER2+ advanced or recurrent disease. Further research is required to delineate the molecular and clinical features of the ∼34% of MC cases with neither HER2 amplification nor KRAS mutations.